Antibacterial properties of the CFTR potentiator ivacaftor

Journal of Cystic Fibrosis

Volumn 13, Issue 5, 2014, Pages 515-519

  Reznikov, Leah R ^a   Abou Alaiwa, Mahmoud H ^a   Dohrn, Cassie L ^a   Gansemer, Nick D ^a   Diekema, Daniel J ^a   Stoltz, David A ^a   Welsh, Michael J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Antibiotic; Cystic fibrosis; Pseudomonas aeruginosa; Quinolone; Staphylococcus aureus

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LINEZOLID; MOXIFLOXACIN; VANCOMYCIN; AMINOPHENOL DERIVATIVE; ANTIINFECTIVE AGENT; CFTR PROTEIN, HUMAN; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIUM ISOLATE; BIOLUMINESCENCE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; GROWTH INHIBITION; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTER MEMBRANE; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; CFU COUNTING; DRUG EFFECTS; LUMINESCENCE; PHYSIOLOGY;

AMINOPHENOLS; ANTI-BACTERIAL AGENTS; COLONY-FORMING UNITS ASSAY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG SYNERGISM; LUMINESCENT MEASUREMENTS; PSEUDOMONAS AERUGINOSA; QUINOLONES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84926083232     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.02.004     Document Type: Article

References (22)

1. Foundation CF Patient registry: annual data report 2011 2011, Cystic Fibrosis Foundation, Bethesda, MD.
2. Van Goor F., Hadida S., Grootenhuis P.D., Burton B., Cao D., Neuberger T., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009, 106(44):18825-18830. [Epub 2009/10/23].
3. Accurso F.J., Rowe S.M., Clancy J.P., Boyle M.P., Dunitz J.M., Durie P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363(21):1991-2003. [Epub 2010/11/19].
4. Heeb S., Fletcher M.P., Chhabra S.R., Diggle S.P., Williams P., Camara M. Quinolones: from antibiotics to autoinducers. FEMS Microbiol Rev 2011, 35(2):247-274. [Epub 2010/08/27].
5. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2012, Clinical and Laboratory Standards Institute, Wayne, PA. 8th ed.
6. Pezzulo A.A., Tang X.X., Hoegger M.J., Alaiwa M.H., Ramachandran S., Moninger T.O., et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012, 487(7405):109-113. [Epub 2012/07/06].
7. Becher A., Schweizer H.P. Integration-proficient Pseudomonas aeruginosa vectors for isolation of single-copy chromosomal lacZ and lux gene fusions. Biotechniques 2000, 29(5):948-950. [52. Epub 2000/11/21].
8. West S.E., Schweizer H.P., Dall C., Sample A.K., Runyen-Janecky L.J. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 1994, 148(1):81-86. [Epub 1994/10/11].
9. Zhang L., Dhillon P., Yan H., Farmer S., Hancock R.E. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000, 44(12):3317-3321. [Epub 2000/11/18].
10. Wong J.K., Ranganathan S.C., Hart E. Staphylococcus aureus in early cystic fibrosis lung disease. Pediatr Pulmonol 2013, 48(12):1151-1159.
11. An M.M., Shen H., Zhang J.D., Xu G.T., Jiang Y.Y. Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2013, 41(5):426-433. [Epub 2013/03/30].
12. Raggio M., Witzmann K., Durmowicz A. Center for drug evaluation and research 2012, [Contract No.: Application Number: 203188ORig1s000].
13. Travis S.M., Conway B.D., Zabner J., Smith J.J., Anderson N.N., Singh P.K., et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999, 20(5):872-879.
14. Nikaido H., Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev 1985, 49(1):1-32.
15. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992, 56(3):395-411. [Epub 1992/09/01].
16. Kelly H.W., Lovato C. Antibiotic use in cystic fibrosis. Drug Intell Clin Pharm 1984, 18(10):772-783. [Epub 1984/10/01].
17. Doring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3(2):67-91. [Epub 2004/10/07].
18. Seddon M., Wise R., Gillett A.P., Livingston R. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother 1980, 18(2):240-242. [Epub 1980/08/01].
19. Frei C.R., Miller M.L., Lewis J.S., Lawson K.A., Hunter J.M., Oramasionwu C.U., et al. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med 2010, 23(6):714-719. [Epub 2010/11/09].
20. Chu D.T., Fernandes P.B. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother 1989, 33(2):131-135. [Epub 1989/02/01].
21. Andriole V.T. The quinolones: past, present, and future. Clin Infect Dis 2005, 41(Suppl. 2):S113-S119. [Epub 2005/06/09].
22. Cook P.J., Andrews J.M., Wise R., Honeybourne D., Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995, 35(2):317-326. [Epub 1995/02/01].